Aquestive therapeutics signs royalty monetization agreement with marathon asset management for up to $125 million

Warren, n.j., nov. 03, 2020 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that it has entered a royalty monetization agreement with an affiliate of marathon asset management, a leading global investment firm (“marathon”), that will result in proceeds to the company of up to $125 million. in exchange for this funding, marathon will be entitled to receive all royalties and other payments due under aquestive's license agreement with sunovion pharmaceuticals inc. (“sunovion”) as a result of sunovion's commercialization of kynmobi™ (apomorphine hci) sublingual film for the acute, intermittent treatment of off episodes in patients with parkinson's disease. net proceeds of the transaction will be used to repay certain senior notes and fund the company's ongoing development and commercialization of its proprietary product pipeline candidates, as well as for working capital purposes. kynmobi received approval from the u.s. food and drug administration (fda) on may 21, 2020. 
AQST Ratings Summary
AQST Quant Ranking